BIOKIN's Novel Dual-Antibody Drug Receives Marketing Approval in China
Stock News
Jun 22
BIOKIN has announced the receipt of a drug registration certificate from the National Medical Products Administration.
This approval grants marketing authorization for the company's internally developed, first-in-class, and novel concept dual-antibody drug conjugate, iza-bren (also known as BL-B01D1).
The drug is the only candidate of its type to have progressed to Phase III clinical trials and is indicated for patients with recurrent or metastatic nasopharyngeal carcinoma.
Eligible patients are those who have experienced treatment failure after receiving at least two prior lines of systemic chemotherapy and PD-1/PD-L1 inhibitor therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.